- Home
- PMTS vs TNGX Comparison
PMTS vs TNGX Comparison
Compare PMTS & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMTS | TNGX |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.1M | 1.4B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | PMTS | TNGX |
|---|---|---|
| Price | $13.86 | $9.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $32.00 | $12.50 |
| AVG Volume (30 Days) | 51.7K | ★ 2.5M |
| Earning Date | 11-04-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $515,576,000.00 | $66,501,000.00 |
| Revenue This Year | $13.70 | $52.80 |
| Revenue Next Year | $8.51 | N/A |
| P/E Ratio | $11.71 | ★ N/A |
| Revenue Growth | 12.48 | ★ 53.29 |
| 52 Week Low | $11.64 | $1.03 |
| 52 Week High | $34.25 | $11.20 |
Technical Indicators
Market Signals| Indicator | PMTS | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 36.40 | 61.80 |
| Support Level | $14.60 | $8.66 |
| Resistance Level | $14.83 | $9.16 |
| Average True Range (ATR) | 0.66 | 0.49 |
| MACD | -0.29 | 0.04 |
| Stochastic Oscillator | 2.23 | 94.16 |
Price Performance
Historical ComparisonAbout PMTS CPI Card Group Inc.
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.